Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A plus hydrodistension for refractory interstitial cystitis/painful bladder syndrome
ACTRN12612000216819Phase 2Completed
- Sponsor
- John Hunter Hospital
- Start
- Jan 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) (2 arms), sponsored by John Hunter Hospital. Primary endpoint: Improvement in O'Leary-Sant problem and symptom scores. Started Jan 2004; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on ACTRN12612000216819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000216819.